Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Cytarabine × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 779 Lymphoid 405 Myeloid 133 Classical hematology 35 Sarcoma 24 Plasma cell 20 CNS 11 Dermatologic 7 Tumor-Agnostic 2 Other solid neoplasm 2 Other neoplasm 1 Other 1 Genitourinary 1 Breast 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 360 pembrolizumab 277 Prednisone 245 enzalutamide 240 Gemcitabine 231 Magnetic Resonance Spectroscopy 228 Radiotherapy 226 Nivolumab 213 Abiraterone Acetate 179 Cisplatin 174 Radiosurgery 167 Leuprolide 167 Sunitinib 150 Carboplatin 139 Specimen Handling 131 Androgen Antagonists 128 bicalutamide 124 Goserelin 123 Ipilimumab 113 Paclitaxel 110 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 104 apalutamide 102 Cyclophosphamide 100 Everolimus 95 Biopsy 94 Sorafenib 92 Bevacizumab 89 cabozantinib 88 abiraterone 88 atezolizumab 84

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00480090 2019-02-15

SLAP

University Health Network, Toronto

Phase 2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡